Last reviewed · How we verify
SEVENFACT®
SEVENFACT®, marketed by Laboratoire français de Fractionnement et de Biotechnologies, is a small molecule with an unclear mechanism of action, currently holding a position in the market without specified primary indications or revenue data. The key strength of SEVENFACT® lies in its protected intellectual property, with the key composition patent expiring in 2028. The primary risk is the lack of detailed clinical trial results and clear primary indications, which may limit its market adoption and competitive positioning.
At a glance
| Generic name | SEVENFACT® |
|---|---|
| Sponsor | Laboratoire français de Fractionnement et de Biotechnologies |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Dizziness
- Headache
- Infusion-related reaction
- Infusion-site discomfort
- Infusion-site hematoma
- Body temperature increase
Key clinical trials
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors (PHASE4)
- Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531) (PHASE2)
- Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEVENFACT® CI brief — competitive landscape report
- SEVENFACT® updates RSS · CI watch RSS
- Laboratoire français de Fractionnement et de Biotechnologies portfolio CI